Introduction
Childhood B-cell precursor acute lymphoblastic leukemia (BCP-ALL) is the most common type of cancer in children. 1 Intensive multiagent chemotherapy and hemopoietic stem cell transplantation allows to cure more than 80% of patients. 2 Nonetheless, some patients are still resistant to standard therapies, which also cause high and often unacceptable acute and chronic organ toxicity, with an increased risk of secondary malignancies. 2 Therefore, new strategies are needed to improve overall survival and decrease treatment-associated morbidity.
Several groups are developing different strategies to induce an in vivo effective and durative anti-leukemia immune response. [3] [4] [5] [6] The most attractive one is the adoptive approach, which is expected to induce both therapeutic T-cell immunity (in the form of tumor-specific effector T cells) and protective T-cell immunity (in the form of tumor-specific memory T cells that can control tumor relapse).
It has been clearly demonstrated that, 7 to be effective in vivo, tumor-antigen-specific T cells should be able to: (i) migrate to tumor-infiltrated tissues to exert a specific anti-tumor cytotoxic activity and proliferate after antigen-exposure, (ii) migrate into lymphoid tissues, where the encounter with antigens induces clonal expansion and differentiation into effector T cells, (iii) produce cytokines and chemokines, which amplify the antitumor response by activating and recruiting other immuneeffector cells implicated in the innate response into the tumor site. 7 Moreover, it has been shown that the presence of antigenprimed CD4 þ T-helper cell-1 (Th-1) is crucial to activate an anti-tumor immune-response. [8] [9] Tumor specific Th-1 cells can mediate an anti-tumor effect via a variety of mechanisms, including the support of the immune response via cytokine production, 10 the induction of proliferation and survival of CD8 þ cytotoxic T lymphocytes (CTL), 11 a direct cytotoxic effect towards the tumor itself, [12] [13] [14] and the capacity to orchestrate the recruitment and activation of innate immune cells. [15] [16] [17] Besides being necessary to properly activate and expand CTLs from the naive T-cell pool, Th-1 cell help is also required for the reactivation of memory CTL. 18 Based on these considerations, an optimal strategy of tumor immunotherapy should be capable to generate and expand in vitro both anti-leukemia Th-1 cells and CTL, able to confer an immediate protection, as well as to subsequently mount a rapid and effective secondary immune response.
With this purpose, we explored an approach for generating an anti-BCP-ALL immune response by using dendritic cells (DC) pulsed with apoptotic BCP-ALL blasts and matured with an immunological stimulus (CD40L), which induces high cytokine production by DC, [19] [20] in particular IL-12, able to polarize the differentiation of T-lymphocytes with a Th-1 profile. 21 In this study, we demonstrate that, after phagocytosis of CD40L þ BCP-ALL cells, DC mature in potent antigen presenting cells (APC) able to cross-present apoptotic leukemic blasts and to generate specific anti-BCP ALL T cells. These T cells present a memory and Th-1 phenotype and are potentially able to reach leukemia-infiltrated tissues and to migrate into lymphoid tissues, where the reactivation of memory T cells takes place.
Materials and methods

CD40L transduction of HBMS lines by lentiviral vector
Human bone marrow stromal cell (HBMS) line was kindly provided by Dr D Campana (St Jude Children' Research Hospital, Memphis, TN, USA) and has been previously described. 22 Details of vector construction are provided elsewhere. 23, 24 Lentivector particles were generated by transient co-transfection of HEK293 T cells with the VSV G glycoprotein containing plasmid pMD-G, the packaging construct pCMVdR8.74 (plasmids kindly provides by Dr Naldini, Università Vita-Salute San Raffaele, Milan, Italy) and the pRRLsin18.cPPTs.hCMV.hCD40L. Wpre transfer constructs. 25, 26 Vector particles were concentrated by ultracentrifugation, and the titer was determined by transduction of ALL-PO cells, as described. 23 HBMS cell line were plated the day before transduction and exposed to a MOI of 100 for 48 h. The medium was then changed, the cells expanded for two weeks and the transduction procedure repeated two additional times with 15-day intervals.
Bystander transfer of functional hCD40L from CD40L þ HBMS line Bone marrow (BM) cells were collected from 15 children with BCP-ALL at diagnosis. In all cases blast infiltration 480% was present and more than 90% of the blasts expressed CD19 antigen and lacked surface Ig (sIg). The Institutional Review Board approved this study and informed consent was obtained from parents or guardians. BCP-ALL blasts were resuspended in RPMI-1640 with 10% FBS at a final concentration of 2 Â 10 6 /ml. Suspension (1 ml) was seeded onto CD40L þ HBMS cell line, previously washed twice with PBS and irradiated. After 24 h of culture, cells were detached by scraping, washed once in RPMI-1640 containing FBS, and analyzed immediately.
Dendritic cell generation
DC were generated using CD14 þ peripheral blood mononuclear cells (PBMC) of healthy donors and then used for standardization of the phagocytosis process. Five couples of BCP-ALL patients and their human stem cell transplantation (HSCT) donors were afterward used for experiments of induction of anti-leukemia CTL. DC were generated from peripheral blood CD14 þ monocytes for each selected HSCT donor. CD14 þ cells were purified by means of magnetically labeled CD14 microbeads (Miltenyi Biotec GmbH, Bergisch-Gladbach, Germany) according to manufacturer's instructions and cultured for five days in RPMI-1640 (Biowest) in the presence of 50 ng/ml of GM-CSF (PeproTech, Rocky Hill, NJ, USA) and 20 ng/ml of IL-4 (PeproTech).
Induction of anti-leukemia CTL
T cells were obtained from mononuclear cells (MNCs) of HSCT donor after negative selection using anti-CD14 magnetically labeled microbeads (Miltenyi) and were co-cultured with CD40L þ BCP ALL cells loaded DC at the 1/5 DC:T cells ratio in the presence of the supernatant obtained during the phagocytosis process. On day 7 and 14, T cell cultures were restimulated with CD40L þ BCP ALL cells loaded DC. IL-2 (50 U/ml) (Chiron, Emerville, CA, USA) was introduced into the cultures at day 8 and every 3-4 days thereafter.
FACS analysis
To detect the maturation stage of DC after phagocytosis, cells were incubated with anti phycoerythrin (PE)-CD83 (Becton Dickinson, San Jose, CA, USA). Aliquots of cultured T cells were collected after 3 weeks of culture and used to determine the expression of various surface markers using Peridinin-
(Becton Dickinson), FITC-coniugated anti-CD45RA, FITC-conjugated anti-CD8 (Becton Dickinson) PE-conjugated, anti-CD4 (Becton Dickinson), PE-conjugated anti-Granzyme (Sanquin, Amsterdam, the Netherlands), PE-conjugated anti-perforin (Becton Dickinson), PE-conjugated anti-CD56 (IQ product, Groningen, The Netherlands) with isotype-matched antibodies (Becton Dickinson) as controls. Surface expression of adhesion molecules was analyzed using PE-anti-CD49d and FITC-anti-CD62L (Chemicon International, Temecula, CA, USA). Surface expression of chemokine receptors was studied by standard indirect flow cytometry staining using the following monoclonal antibodies: anti-CCR7 (Pharmingen San Diego, CA, USA), anti-CXCR4 (Pharmingen), followed by incubation with anti-mouse biotin (Jackson Immunoresearch, West Grove, PA, USA) and PEconjugated streptavidin (Pharmingen). Ten thousand cells were acquired with a FACScan flow cytometer (Becton Dickinson).
Apoptotic-BCP-ALL cell phagocytosis by dendritic cells
For standardization of method the apoptotic blasts generation the following protocol was used: Intracellular dye carboxyfluorescin diacetate succymidil ester (CFSE) (Molecular Probes, Eugene, OR, USA) BCP-ALL cells and CD40L þ BCP-ALL cells were induced into apoptosis by UVB irradiation for 90 s, followed by 2 h incubation in RPMI without FBS. After incubation, cell death was assessed by Trypan blue exclusion, externalization of phosphatidylserine using FITC-labeled annexin V (PharMingen), and staining with PI. Apoptotic cells were then cultured with immature DC at 2:1 ratio, at 37 or 41C for 4 h. The gate was set on DC using both FSC/SSC, and the green CSFE was measured on FACScan (Becton Dickinson). For generation of CD40L þ BCP-ALL pulsed DC: apoptotic CD40L þ BCP-ALL were cultured with immature DC for 24 h. After incubation the supernatant was collected and used for IL-12p70 evaluation by ELISA 27 and for addition to the co-culture with T cells.
Mixed leukocyte reaction
BCP-ALL cells-loaded, CD40L þ BCP-ALL cells loaded and control DC were added in graded numbers to 2 Â 10 5 purified allogeneic T cells in 96-well round-bottom microtest plates. 
Polarization of naive T lymphocytes into Th1 or Th2 effectors
Lymphocytes enriched in naive T cells were obtained from cord blood of normal deliveries by panning on CD6-coated plastic plates. T-cells (1 Â 10 6 /ml) were co-cultured for 6 days with BCP-ALL cells-loaded, CD40L þ BCP ALL cells loaded and control DC cells at a ratio of 2:1. At the end of the incubation, the production of IL-4 and IFN-g was determined by flow cytometry intracellular-staining 27 .
51 Cr release cytotoxicity assay Cytotoxicity was measured in an 8-h 51 Cr release cytotoxicity assay. BCP-ALL cells were labeled for 1 h with 51 Cr and washed three times with RPMI þ 10% FBS. Expanded anti-leukemia T cells were cultured with 5 Â 10 3 target cells at E:T ratio of 30:1, 10:1, in 200 ml of complete RPMI medium in U-bottomed 96-well plates. After 8 h, 30 ml of supernatant were collected, 170 ml of scintillation liquid (PerkinElmer Life Science, Boston, MA, USA) was added to the supernatant and the radioactivity was then detected by b-scintillation counter (PerkinElmer Life Science), as counts per minutes (CPM). The percentage of specific lysis was calculated using the following formula: ((cpm experimental releaseÀcpm minimal release)/(cpm maximal releaseÀcpm minimal release) Â 100). Minimum 51 Cr release was determined from wells containing target cells and medium only. Maximum 51 Cr release was determined from wells containing target cells with 100 ml of 5% Triton X-100 (Sigma, St Louis, MO, USA).
Chemotaxis assays
Anti-leukemia T cells were labeled with 25 mC i of 51 Cr for 1 h and washed three times with complete RPMI medium. T cells (5 Â 10 5 ) were subsequently placed in the upper chamber of Transwell insert (5-m pore size; Corning Costar, Corning, NY, USA). Inserts were placed in wells containing medium alone (basal) or medium plus chemokine. CXCL12 and CCL19 were purchased from PeproTech. Chemokines were used at optimal concentration determined by titration. Every experiment was performed in duplicate. Radioactivity in bottom wells (migrated cells) was evaluated after 60 min with a b-scintillation counter. Results are expressed as the migration index of T cells in response to the chemokine versus the basal condition.
Cytokine analysis
In three selected experiments, on day 21 of culture, antileukemia T cells were immunoselected to evaluate the capacity of CD8 þ and CD4 þ cells to produce immunoregulatory cytokines in response to BCP-ALL. CD4 þ and CD8 þ T cells were purified by means of magnetically labeled with anti-CD4 or anti-CD8 microbeads (Miltenyi Biotec) according to manufacturer's instructions and incubated either in the absence or with BCP-ALL cells, MNCs obtained from HSCT-donor and patient non-leukemic MNCs collected before transplantation (0.5 Â 10 6 /ml). Supernatant (50 ml) was collected after 24 h and the cytokine content was then determined by Multiplex Fluorescent Bead Immunoassay (FBI, Dako) following manufacturer's recommended protocol.
Statistical analysis
Student's t-test was used to evaluate the differences between groups. Po0.05 was considered to be statistically significant.
Results
Dendritic cell maturation induced by CD40L þ BCP-ALL cells
As it has already been demonstrated that the CD40L molecule can be efficiently transferred from a donor fibroblastic cell line, 28, 29 we explored the effectiveness of CD40L molecular transfer onto the BCP-ALL blast surface from a CD40L-expressing HBMS cell line. The CD40L encoding gene was transduced into the HBMS cell line by a lentiviral vector, to obtain a stable integration and expression for at least 4 months. 24 Following transduction, more than 80% of cells became CD40L þ . 24 Moreover, BCP-ALL blasts cultured on CD40L þ HBMS acquired CD40L molecules (mean ¼ 43.2%, range 33-57.5% of positive viable blasts, n ¼ 10) and remained CD40L þ for at least two days. 24 To study if the expression of CD40L on apoptotic cells altered the DC phagocytosis process, we labeled CD40L þ or CD40LÀ BCP-ALL cells with the intracellular dye CFSE, then induced their apoptosis by UV irradiation and co-cultured the apoptotic cells with immature DC at 2:1 blasts cells/DC ratio. As shown in Figure 1a , in 3/3 cases tested, after 2 h of UV irradiation, more than 30% of blasts cells appears in early apoptosis (Annexin þ / PIÀ), with no relevant difference between CD40L positive and negative BCP-ALL cells (mean ¼ 31%, range ¼ 28-35%; mean ¼ 33.3%, range ¼ 30-37%, respectively for CD40L þ and CD40LÀ cells).
When BCP-ALL cells were cultured with immature DC for 4 h, 40% of DC became fluorescent and no significant difference was observed when DC were cultured with CD40L þ or CD40LÀ BCP-ALL cells (mean ¼ 43.5%, range ¼ 30-55%; mean ¼ 44.2% range ¼ 34-53%, respectively; n ¼ 3) (Figure 1b) . Control DC incubated with apoptotic cells under 'cold' conditions (41C) did not exhibit positive fluorescence, indicating that DC fluorescence was due to apoptotic-cell To study if phagocytosis of CD40L þ blasts induced the functional maturation of DC, we cultured immature DC with CD40L þ or CD40LÀ BCP-ALL cells for 24 h and then analyzed the expression of membrane CD83 and the production of IL12p70. As shown in Figure 2a , in all cases tested, CD40L þ BCP-ALL cells-pulsed DC expressed high levels (mean ¼ 61.2%, range ¼ 50-70%, n ¼ 5) of CD83, while no CD83 upregulation was observed if CD40L-negative cells were used. In addition, maturation of DC resulted in higher stimulation of proliferative allogeneic T-cell responses, as measured in standard mixed leukocyte reaction (MLR) assay (Figure 2b) . Moreover, CD40L þ BCP-ALL cells-loaded DC secreted considerable amount of IL12p70 (mean ¼ 6.0, range ¼ 3-6.5 ng/ml, n ¼ 5). In two selected cases, we examined the nature of primary allogeneic T-cell response induced by CD40L þ or CD40L-BCP-ALL cells-pulsed DC. We tested the IFN-g and IL-4 production by flow cytometry intracellular-staining analysis of naive lymphocytes co-cultured with CD40L þ or CD40LÀ BCP-ALL cells-loaded DC. CD40L þ BCP-ALL cells-loaded DC induced a very high Th1 polarization (more than 30% of IFN-g þ CD3 þ cells, range ¼ 26-42%), as anticipated by the high levels of IL-12p70 production ( Figure 2c ).
Generation of anti-BCP ALL T cells
As a result of the capacity of the above-described method to obtain an efficient DC maturation accompanied by phagocytosis of apoptotic CD40L þ BCP ALL cells, this protocol was chosen to generate anti-BCP-ALL T cells starting from five HSCT donors. Donor derived-T cells and DC pulsed with coupled patient derived-CD40L þ BCP ALL cells were co-cultured for 3 weeks.
To confirm that CD40L-expressing ALL cells were not responsible for direct T-cell stimulation, an aliquot of cells was phenotypically analyzed at the end of the pulsing phase and viability was measured on CD19 þ ALL cells. After 24 h from irradiation, ALL viability, measured by FACS analysis (propidium staining), was always o5% (data not shown) and only leukemia-cell debris were present in the cultures, thus indicating that only loaded DCs were responsible for specific T-cell growth.
At the end of incubation, T cells were analyzed for the expression of different surface markers by FACS analysis and for their capacity to recognize and kill patient BCP-ALL cells.
The phenotypical analysis of cultured cells showed that, after co-culture, both CD4 and CD8 T cells were equally represented (average levels of 45 and 42%, respectively; Figure 3) , with an increased proportion of CD8 T cells in all cases (mean ¼ 26% at beginning and 42% at the end of the culture). In addition, a considerable proportion of T cells expressed a naïve phenotype at the beginning of the culture (CD45RA þ CCR7 þ , mean ¼ 40%, range ¼ 25-60%), but, after 3 weeks, the percentage of naive T cells drastically decreased (mean ¼ 10%, range ¼ 5-30%) and most of T cells showed a memory phenotype (CD45RAÀ): Central Memory (TCM, CCR7 þ , mean ¼ 31%, range ¼ 13-46%) and Effector Memory (TEM, CCR7-, mean ¼ 40%, range 26-61%) phenotype. The average proportion of Terminal Effector Memory CD45RA þ cells (TEM-RA þ ) decreased during the culture, going from 29 to 19%. NKT and NK cells, which were present at variable percentages, almost disappeared after the co-culture, being o3% for both populations (Figure 3) .
Intracytoplasmic staining of Granzyme B showed that almost 98% of CD8 þ cells expressed the molecule. Also the average level of expression of perforin increased from the beginning of the co-culture, going from an average expression of 34 up to 65% (Figure 4a) .
The anti-leukemia activity of cultured T cells was tested in an 8-h cytotoxicity assay. Figure 4b shows the cytolytic activity of Additionally, experiments of Class-I and Class-II MHC blocking were performed on three different donors. Anti-class I blocking determined a significant inhibition of specific ALL killing (average level of inhibition ¼ 92%, range ¼ 88-93%), thus demonstrating a major contribution of CD8 T cells in the process of leukemia cells cytotoxicity. On the contrary, Class-II blocking was not accompanied by any significant inhibition of T-cell killing (o5%).
In view of their potential use for adoptive immunotherapy, we tested all anti-leukemia CTL lines against both MNCs obtained from HSCT-donor (as an in vitro control for graft autoreactivity) and patient non-leukemic MNCs collected before transplantation (as an in vitro control for the graft-versus-host disease (GVHD). At the 30:1 E/T ratio tested, all cultures showed a low cytotoxic activity (p20%) against both controls (Figure 4b ). To test if the cytolytic activity was oriented towards normal B-lineage or HLA allo-antigens, additional experiments were performed on HLA-matched pre B leukemia cells (level of cytotoxicity o5% in 3 anti-BCP-ALL T-cell tested against two primary ALL samples) and patient CD19-sorted normal B cells (two donors tested), demonstrating the absence of significant killing (level of cytotoxicity o5%, in both sets of experiments). Additionally, no significant cytolytic activity was observed towards the K562 cell line (average level of lysis ¼ 6.3%, range ¼ 5-8%, as shown in Figure 4b ).
Functional characterization of anti-BCP ALL T cells
The first requirement for the potential use of these anti-BCP-ALL T cells for adoptive immunotherapy is that these cells are able to amplify the anti-tumor response, by producing different cytokines, and that a proportion of these cells are Th-1 cells. 8, 9 For this purpose, we analyzed, in three selected cases, the production of IL-2, IL-5, IL-6, IL-10, IFN-g and TNF-a by CD4 and CD8 immunoselected anti-leukemia T cells, after incubation with BCP-ALL blasts or MNCs obtained from HSCT-donor or patient non-leukemic MNCs. In all cases ( Figure 5 ), CD4 þ or CD8 þ T cells produced very low levels of Th-2 cytokines (IL-5, IL-6, IL-10), whereas both CD4 þ and CD8 þ T cells produced IFN-g (mean ¼ 655 pg/ml, range ¼ 454-1278 pg/ml; mean ¼ 816 pg/ml range ¼ 631-1019 pg/ml, respectively) and TNF-a (mean ¼ 723 pg/ml, range ¼ 290-1215 pg/ml; mean ¼ 523 pg/ml, range ¼ 363-679 pg/ml, respectively) after co-culture with BCP-ALL cells. In 3/3 cases, CD4 þ T cells were also able to produce IL-2 (mean ¼ 220 pg/ml, range ¼ 177-245 pg/ml). CD4 and CD8 T cells produced little amounts of cytokines in response to MNCs obtained from HSCT-donor or patient non-leukemic MNCs. The second requirement for the potential use of anti-BCP-ALL T cells for adoptive immunotherapy is that these cells are capable to migrate into the sites where acute leukemia cells infiltrate and proliferate (e.g., bone marrow) [30] [31] [32] and into the lymphoid tissues, where the encounter with antigen presented 
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by APC induces clonal expansion and differentiation into effector T cells. 33 With the aim of exploring the trafficking properties of anti-BCP ALL T cells, we examined the surface expression of adhesion molecules and of chemokine receptors and the chemotactic activity.
We analyzed the expression of the adhesion molecules implicated in homing to the bone marrow (CD49d, VLA-4) 34 and to lymph nodes (CD62L) 35, 36 (Figure 6a) . A significant proportion of CD62L þ cells (mean ¼ 45%, range ¼ 44-46%; n ¼ 5) was detectable within anti-BCP-ALL T cell population, whereas CD49d was expressed on the cell surface of 498% of anti-BCP-ALL T cells.
To investigate the chemotactic capacity of anti-BCP-ALL T cells, we analyzed the expression of chemokine receptors specifically involved in the process of trafficking into different tissues. Most anti-BCP-ALL T cells expressed CXCR4, a chemokine receptor implicated in the recruitment of cells into the bone marrow (average expression ¼ 71%; range ¼ 56-80%; n ¼ 5; Figure 6a) . 37, 38 Moreover, an average of 50% of anti-BCP ALL T cells expressed high levels of CCR7 (range, 55.3-68.5%; n ¼ 5; figure 6a), whose ligand (CCL19) is involved in the process of migration into the spleen and lymph nodes. 39, 40 We next evaluated the chemotactic response of anti-BCP ALL T cells to chemokines. CXCL12, the CXCR4 ligand, induced robust chemotaxis of T cells (mean ¼ 3.0, range ¼ 1.8-3.9, n ¼ 4), while CCL19, the CCR7 ligand, induced lower, but still significant migration of these cells (mean ¼ 2.1, range ¼ 1.4-2.8, n ¼ 4), as shown in Figure 6b .
Discussion
Different in vitro and in vivo mouse models have shown that the immune system can recognize and reject tumors by the interaction with tumor-specific or associated antigens. 7, 41, 42 These findings have prompted the investigation of anti-tumor immune protocols in the human setting, both by active immunization and adoptive transfer of ex vivo expanded immune cells. Nevertheless, Phase-1 trials in humans clearly demonstrated that objective anti-tumor clinical responses are rare and often transient. 7 Inefficacy of anti-tumor immunotherapy probably depends on different factors, mainly represented by the inability of sufficient lymphocyte numbers to migrate and reach the site of cancer growth, 43 the failure of tumor-antigen-specific T cells to produce cytokines (which amplify the anti-tumor immune-response), and the presence of mechanisms of tumor immune escape and evasion. 43 Moreover, the in vivo observed transient efficacy could depend on the lack of functional Th-1 cells, necessary to properly activate CTLs from both the naive and memory T-cell pool and to orchestrate the recruitment and the activation of innate immune cells. These issues lead to the concept that tumor-antigen-specific T cells, to be effective in vivo, besides exerting a cytotoxic in vitro activity towards the selected tumor target, must also be in the correct state of activation and differentiation in order to mediate an in vivo effective and long-lasting anti-tumor immune-response and potentially counter-attack the mechanisms of immune evasion. 44 To devise a BCP-ALL targeted immune approach, we have generated an easy and reproducible method to concomitantly load, and strongly mature, DCs, using apoptotic CD40L-expressing leukemic blasts. Among the many molecules described in the literature, we chose to use the CD40L molecule because, besides its capacity to increase the antigen-presenting capacity of DCs by upregulating the expression of costimulatory molecules (including CD80 and CD86), adhesion and MHC molecules, it also increases the ability to process antigens and induces a robust production of IL-12, IL-15 and IL-7. 19, 20, 45, 46 With the aim of producing CD40L-expressing leukemia cells, we adopted a bystander inter-cellular transfer method after coculture with CD40L-gene transduced fibroblasts. In fact, direct gene transfer of leukemia cells can be difficult, often producing variable and not reproducible levels of target molecule expression among different samples tested. Moreover, the use of high viral MOI induces high cell death, therefore representing an obstacle when scaling-up the approach for clinical application. As reported by others 28 and us, 24 an efficient surface expression of hCD40L can be obtained after co-culture of leukemia cells with human fibroblasts previously transduced to express high levels of the molecule. 
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After co-culture with CD40L þ BCP ALL pulsed DCs, an enriched CD8 þ T-cell population was detected with high intracytoplasmic expression of perforin granules and Granzyme. In line with these results, we detected significant levels of BCP-ALL blast killing by CTLs for all tested co-cultures, almost totally mediated by CD8 T cells, as demonstrated by MHC Class I blocking experiments. The high levels of perforin and Granzyme detected and the main role of CD8 T cells are in line with experimental models already described in the literature, 47 which demonstrated a main role of the perforin pathway in the process of leukemia lysis. Cytotoxicity experiments towards controls showed low levels of cytotoxicity towards patient nonleukemic cells, MNCs obtained from HSCT-donors and the K562 cell line. Moreover, cytotoxicity experiments performed on HLA-matched pre-B leukemia cells and patient CD19-sorted normal B cells did not reveal any significant killing activity, thus supporting the hypothesis that the killing activity is not oriented either towards a B-lineage marker, or an allo-antigen, but to a leukemia-associated antigen. T-cells could, in fact, potentially recognize a leukemia-specific peptide derived from an undetected oncogenic protein generated as a consequence of a genetic aberration. Moreover, the role of a minor histocompatibility antigen could not be excluded. Further studies are required to identify the involved leukemia-specific antigens.
Besides being capable to recognize and kill the specific target, cultured T cells must also have appropriate functional characteristics to hypothesize the maintenance of a correct functionality in vivo. Firstly, as demonstrated by Kaech et al., 48 efficient priming of T cells is accompanied by the acquisition of a memory phenotype. In our experiments, we have demonstrated the capacity of CD40L þ BCP ALL cells pulsed-DC to induce the differentiation and proliferation of memory T cells, in particular TCM and TEM and, to a lesser extent, TEM RA þ . These subsets are endowed with different homing ability to lymphoid or non-lymphoid tissues, to proliferate in response to antigen or cytokines and to kill the specific target. 33, 49 TCM re-circulate in the blood and secondary lymphoid organs and have limited effector function, but they have a high expansion potential and are capable to become effector cells upon secondary stimulation. These cells are important in the secondary immune-response. By contrast, TEM and TEM RA þ home to peripheral tissues, can rapidly produce effector cytokines (such as IFN-g) upon antigenic stimulation, but have limited proliferative capacity. 33 All T-cell memory subsets may be relevant for leukemia immunotherapy: the greater capacity of TCM than TEM to persist in vivo and to mediate protection for their high proliferative potential, confer them the potential ability to control tumor relapse. However, the strong capacity to mediate effector function of TEM and TEM RA þ cells represents a first line of defense in non-lymphoid tissues and confers them the potential ability to immediately kill the leukemia target.
After demonstrating the presence of a specific cytotoxic activity accompanied by the acquisition of memory phenotype, we next investigated if, during the process of maturation and acquisition of a memory phenotype, T cells also acquired an effector function with production of immunoregulatory cytokines. In particular, we have analyzed if CD4 þ T cells, obtained after immuno-magnetic selection, had a Th-1 profile. Zinkernagel et al. 50 demonstrated the crucial role of Th-1 cells in CTL induction. They showed that the activation of specific CD8 lymphocytes in vivo was dependent on the presence of CD4 helper cells. In addition, Cassell et al. 51 demonstrated that CD4 and CD8 cells must recognize antigens on the same APC to have an in vivo generation of antigen-specific CTL; antigen presented by two distinct APC did not induce CTL activation. In our model, we have demonstrated that, after co-culture with CD40L þ BCP ALL cells pulsed DC, CD4 T cells differentiate into Th-1 effectors able to specifically produce cytokines (IFN-g, TNF-a, IL-2) in response to unmanipulated BCP-ALL cells.
The explanation of a preferential expansion of Th-1 cells may rely on the high levels on IL-12p70 detected in our system. In fact, the generation of Th-1 cells is strictly dependent on IL-12 p70. This cytokine is secreted by activated APC, such as DC, which have been widely demonstrated to be capable of producing the highest levels of such molecule. The extent of IL-12p70 production is strongly dependent on the kinetic of DC activation.
52,53 DC produce IL-12p70 only within 8-16 h after challenge with IL-12-inducing stimuli, and at later time points become refractory to further stimulation. 52, 53 Therefore, only recently activated DC can efficiently prime Th-1 responses whereas 'exhausted' DC (424 h after activation) preferentially prime Th-2 and non-polarized T-cell responses. Based on these findings, we have decided to use the supernatant obtained during the 24h-phagocytosis process (enriched in IL12p70), to support, in concert with exogenous IL-2, T-cell proliferation and Helper and cytotoxic T Lymphocytes for immunotherapy of BCP-ALL G D'Amico et al differentiation through the co-culture. Therefore, the presence of Th-1 CD4 T cells in our tested co-cultures may be explained by the use of a conditioned culture medium enriched in high levels of IL-12. The presence of an augmented fraction of Th-1 CD4 T cells is of advantage for their well-known capacity to support the viability and self-renewal of CD8 T cells during prolonged cultures. Montagna et al. 47 demonstrated that the absence of CD4 lymphocytes for the production of anti-leukemia CTL during in vitro co-culture, impairs the generation and long-term maintenance of CTL. As also observed in our cultures, the presence of Th-1 CD4 T cells may be the main factor responsible for maintenance of CD8 cells. Generated CD8 T cells were not only characterized by the capacity to express perforin and Granzymes (the main way by which CD8 þ T cells eliminate tumor cells), but also by the secretion of IFN-g and TNF-a, which contribute to host defense in several ways, necessary to activate and support both adaptive (by recruitment and activation of professional APC at the site of tumor killing) 54 and innate immune response (by attraction and activation of macrophages and NK cells). [55] [56] [57] The trafficking of immune cells is regulated by a complex interaction of chemokines and adhesion molecules and cell surface receptors. It has been demonstrated that T cells, during the process of homing into the bone marrow, require VCAM-1 constitutively expressed by bone marrow microvasculature and stromal cells, 58 which binds the integrin CD49d. This latest molecule is expressed at high levels by activated, but not naive, CD4 and CD8 cells. Furthermore the CD62L molecule, expressed by naive lymphocytes and central memory T cells, is involved in the extravasation of TCM into lymph-nodes. 59, 60 In line with these observations, we found that anti-BCP ALL T cells expressed high levels of CD49d and, to a lesser extent, CD62L. As for adhesion molecules, also chemokines are differentially expressed in various tissues in physiological conditions or during inflammation. It has been shown that the axis CXCR4/CXCL12 is crucial to guide the homing of memory T cells and other hemopoietic cells into bone marrow, 58 whereas the migration of both naive T cells and TCM to regional lymph nodes is primarily guided by the axis CCR7/ CCL19. 60 We found that anti BCP-ALL T cells express high levels of both CXCR4 and CCR7 and the in vitro response to chemokines confirmed the pattern of expression of the specific chemokine receptors. Anti-BCP-ALL T cells, in fact, migrated in response to CXCL12 and CCL19.
The pattern of expression of chemokine receptors and the capacity to migrate upon stimulation to chemokines render these cells a potential tool for leukemia immunotherapy due to their potential capacity of reach tumor-infiltrated tissues (to kill the specific target) and lymph nodes (where they can get in contact with the specific antigens presented by activated professional APCs).
In conclusion, this is the first time, at our knowledge, that a complete analysis of functional properties (cytotoxicity, memory phenotype, cytokine profile and trafficking) of anti-BCP ALL T cells has been thoroughly characterized. We have demonstrated that the co-culture of CD40L þ BCP-ALL cells-pulsed DC with HSCT-donor T cells generates specific and functional anti-BCP-ALL-T lymphocytes with memory phenotype, potentially able to reach leukemia-infiltrated tissues and to migrate into lymphoid tissues, where the reactivation of memory T cells take place. Moreover, this culture system induces the generation of functional and specific anti-BCP-ALL-Th-1 cells and CD8 þ T cells potentially able to orchestrate the anti-tumor immuneresponse. The method of bystander transfer of CD40L from donor fibroblasts have already been used in clinical trials 61 and can therefore open the way for the currently proposed approach to be used in human trials.
